EPISODE · Jul 7, 2022 · 32 MIN
Rethinking Research
from Health & Veritas
Howie and Harlan discuss a concerning new COVID-19 variant, the discovery casting doubt on a major fish-oil study, and the need for new models of funding research. Links: "New Omicron subvariant Centaurus could be the most immune-evasive yet, expert warns" "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia" "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy" Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.
Embed this episode
Ready to play
Rethinking Research
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.